Latest News Archive
Please select Category, Year, and then Month to display items
29 March 2023
|
Story Samkelo Fetile
|
Photo Simba Matema
From left to right: Prof Jean Bernard Lekana-Douki, Director General at the CIRMF; Prof Francis Petersen, Rector and Vice-Chancellor of the UFS; and Prof Jean-Fabrice Yala, Scientific and Technical Director at the CIRMF.
The University of the Free State (UFS) recently welcomed senior members from the International Centre for Medical Research in Franceville (CIRMF), Gabon to sign a Memorandum of Understanding (MoU) between the two entities.
CIRMF is a non-profit medical research centre that was established in 1974. Its primary focus is on diagnosing infectious diseases that pose immediate problems in Gabon and the Central African sub-region. The centre is dedicated to improving public health through various initiatives, including the training of Gabonese health executives in doctoral and post-doctoral education.
“The signing of the MoU with CIRMF is a step in the right direction as the UFS continues to strengthen its footprint on the African Continent. This is seminal in driving the university’s internationalisation processes and opening an avenue to expanding research networks, especially in the African continent,” said Bonolo Makhalemele, Coordinator of strategic projects at the Office for International Affairs, UFS.
In the interest of developing broader research collaborations, the CIRMF delegation met with some UFS academics in a series of engagements, particularly in the Health Sciences Faculty and the Natural and Agricultural Sciences Faculty. “The integration of knowledge and practices that emanate from the continent provides opportunities for the co-creation of knowledge that can be shared with the rest of the world,” said Kagiso Ngake, Coordinator for Partnerships, Collaborative Degrees, and Outgoing Mobility at the Office for International Affairs, UFS.
A concrete roadmap was established to formalise the collaborations that resulted from these engagements and will commence as soon as April 2023. “We have laid a solid foundation and are on the way to a strong and rich partnership!” exclaimed Prof Jean Bernard Lekana-Douki, Director General at the CIRMF.
Prof Francis Petersen, Rector, and Vice-Chancellor of the UFS, further highlighted how the newly established partnership with the CIRMF aligns with the mandate of the UFS Vision 130 of expanding the UFS Africa research network.
UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08
The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.
The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.
The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.
“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.
“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.
According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.
The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.
According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.
The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.
Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004